https://www.selleckchem.com/products/4sc-202.html
s likely to have a good response and clinical benefits to antiPD-1/L1 immunotherapy. This study highlights the prognostic value of 25 m6A regulators in CC. The m6A modification is related to immune regulation and the formation of TME heterogeneity and complexity. An m6A scoring signature to clarify the individual m6A modification pattern could enhance our understanding of TME immune cell-infiltrating characterization and guide immunotherapy strategies.For the diagnosis and prognosis of glioma, the development of prognostic biomarkers is
Aimer
Commentaire
Partagez
